The San Francisco-based company’s stock fell 38% to $20.89 in extended trading, hitting a new 52-week low. The decline follows a difficult period for the digital healthcare platform, which had already seen its share price retreat 39% over the preceding three months. Investors reacted sharply to a revision in revenue expectations that suggests slowing momentum for the platform.
Revised Guidance and Leadership Transition
Doximity adjusted its full-year sales forecast to a range of $642.5 million to $643.5 million, modifying its previous estimate of $640 million to $646 million. More critically, the company projected current-quarter revenue between $143 million and $144 million. That figure fell significantly short of the $150.4 million expected by analysts polled by FactSet, signaling a cooling in the company’s near-term growth trajectory.

Comments (0)
No comments yet. Be the first!